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Introduction {#acn3697-sec-0005}
============

The pathological hallmarks of Alzheimer\'s disease (AD) include the extracellular deposition of protein amyloid beta (A*β*) in brain parenchyma and blood vessel walls, and the intraneuronal accumulation of hyperphosphorylated tau (p‐tau).[1](#acn3697-bib-0001){ref-type="ref"} According to the prevailing amyloid hypothesis, aggregation and tissue deposition of A*β* precede p‐tau driven neurofibrillary degeneration and anticipate the clinical onset of the disease by several years.[2](#acn3697-bib-0002){ref-type="ref"}, [3](#acn3697-bib-0003){ref-type="ref"}, [4](#acn3697-bib-0004){ref-type="ref"} Positron emission tomography (PET) with fibrillary A*β*‐specific radiotracers and the cerebrospinal fluid (CSF) quantitative assay of the 42 amino acid form of A*β* (A*β*42) provide in vivo evidence of brain A*β* deposition and are included in current research diagnostic criteria for AD.[5](#acn3697-bib-0005){ref-type="ref"}, [6](#acn3697-bib-0006){ref-type="ref"} However, despite the analytical and clinical validation and the established inverse correlation with amyloid‐related neuropathological changes, the detection of CSF A*β*42 still suffers from limitations.[7](#acn3697-bib-0007){ref-type="ref"}, [8](#acn3697-bib-0008){ref-type="ref"} A*β*42 is highly labile and prone to aggregate, which makes its concentrations susceptible to variation in the preanalytical processing.[9](#acn3697-bib-0009){ref-type="ref"}, [10](#acn3697-bib-0010){ref-type="ref"}, [11](#acn3697-bib-0011){ref-type="ref"} Furthermore, CSF A*β* levels may vary significantly among individuals, leading to a misinterpretation of test results in the presence of constitutively high or low quantities of A*β*42 relative to chosen diagnostic "cut‐off values". These and perhaps other factors might also be responsible for the reported lack of optimal correlation between CSF A*β*42 values and amyloid‐PET[12](#acn3697-bib-0012){ref-type="ref"} or neuropathological findings.[8](#acn3697-bib-0008){ref-type="ref"}, [13](#acn3697-bib-0013){ref-type="ref"} To overcome these limits, several authors proposed to evaluate the ratio between A*β*42 and the 40 amino acid form of Aβ(A*β*40) CSF concentrations instead of that of A*β*42 alone.[14](#acn3697-bib-0014){ref-type="ref"}, [15](#acn3697-bib-0015){ref-type="ref"}, [16](#acn3697-bib-0016){ref-type="ref"}, [17](#acn3697-bib-0017){ref-type="ref"}, [18](#acn3697-bib-0018){ref-type="ref"} Given that A*β*40 is a more stable peptide which is not significantly decreased in AD,[19](#acn3697-bib-0019){ref-type="ref"} it has been hypothesized that the CSF A*β*42/A*β*40 ratio may improve the diagnostic accuracy by allowing the normalization with respect to the sources of A*β*42 level variability unrelated to the AD pathology burden. Increasing evidence supports, indeed, the better diagnostic performance of A*β*42/A*β*40 ratio in comparison to A*β*42 alone.[15](#acn3697-bib-0015){ref-type="ref"}, [16](#acn3697-bib-0016){ref-type="ref"}, [20](#acn3697-bib-0020){ref-type="ref"} Specifically, the A*β*42/A*β*40 ratio showed a better accordance with amyloid‐PET findings[17](#acn3697-bib-0017){ref-type="ref"}, [21](#acn3697-bib-0021){ref-type="ref"}, [22](#acn3697-bib-0022){ref-type="ref"}, [23](#acn3697-bib-0023){ref-type="ref"}, [24](#acn3697-bib-0024){ref-type="ref"} and an improved diagnostic accuracy also in a clinical setting when CSF biomarker assays gave discordant results.[18](#acn3697-bib-0018){ref-type="ref"}, [25](#acn3697-bib-0025){ref-type="ref"}, [26](#acn3697-bib-0026){ref-type="ref"} However, to date, the relationship between antemortem CSF A*β*42/A*β*40 ratio with postmortem AD pathology has not been systematically studied. Aiming to contribute to the issue of the added diagnostic value of CSF A*β*42/A*β*40 ratio in the clinical setting, we tested the hypothesis that the CSF A*β*42/A*β*40 ratio better predicts the burden of AD‐related neuropathological changes than CSF A*β*42 alone. To this aim, we took advantage of a large series of neuropathologically verified cases of Creutzfeldt‐Jakob disease (CJD) and other rapidly progressive dementias (RPDs), in which the CSF biomarker assessment was performed, on average, only a few months before death.

Methods {#acn3697-sec-0006}
=======

Patient selection {#acn3697-sec-0007}
-----------------

We studied patients affected by RPD referred for diagnosis to the Laboratory of Neuropathology (NP‐Lab) at the Institute of Neurological Sciences of Bologna between January 2005 and December 2017. Inclusion criteria were limited to the availability of sufficient and qualitatively adequate postmortem brain tissue for AD neuropathological diagnosis and staging, and a CSF sample of sufficient volume to complete all assays and collected within 36 months from death. The screening of NP‐Lab database yielded a total of 211 suitable cases (Fig. [S1](#acn3697-sup-0001){ref-type="supplementary-material"}). Primary neuropathological diagnosis included CJD (*n* = 159), AD (*n* = 12), dementia with Lewy bodies (DLB, *n* = 4), AD/DLB mixed pathologies (*n* = 5), encephalitis (*n* = 7), vascular dementia (*n* = 6), primary central nervous system malignancy (*n* = 5), Wernicke\'s encephalopathy (*n* = 3), hypoxic encephalopathy (*n* = 2), progressive supranuclear palsy (*n* = 1), variably protease‐sensitive prionopathy (*n* = 1), and progressive multifocal leukoencephalopathy (*n* = 1). Finally, in five cases, neuropathological investigations did not reveal a significant specific pathology to reach a definitive diagnosis.

All subjects gave written informed consent for the use of their clinical data for research purposes and the study was approved by the local ethical review board.

Neuropathological examination {#acn3697-sec-0008}
-----------------------------

Neuropathological examination was performed using standardized procedures as described.[13](#acn3697-bib-0013){ref-type="ref"} Briefly, tissues from the right hemisphere, brainstem, and cerebellum were rapidly frozen at −80°C, while the left parts of the brain were fixed in 10% formalin. Samples from the fixed hemisphere were taken from 23 brain regions, according to a standardized protocol.[27](#acn3697-bib-0027){ref-type="ref"}

Histopathological examination was performed on seven *μ*m thick sections of formalin‐fixed and paraffin‐embedded brain tissue blocks. All sections were stained hematoxylin‐eosin for screening. Also, immunohistochemistry with antibodies specific for PrP (3F4, dilution 1:400, Signet Labs), hyperphosphorylated tau (AT8, dilution 1:100, Innogenetics), and A*β* (4G8, dilution 1:5000, Signet Labs) were applied to all cases. To this aim, several brain regions were stained, mainly following established consensus criteria.[1](#acn3697-bib-0001){ref-type="ref"}, [28](#acn3697-bib-0028){ref-type="ref"}, [29](#acn3697-bib-0029){ref-type="ref"}, [30](#acn3697-bib-0030){ref-type="ref"} Additionally, stainings for alpha‐synuclein (LB509, dilution 1:100, Thermo Fisher Scientific), hyperphosphorylated TDP‐43 (phospho Ser 409/410‐1 polyclonal antibody, 1:1000, CosmoBio Co), anti‐HLA‐DR (CR3/43, 1:400, Agilent Dako), GFAP (6F2, 1:100, Agilent Dako), CD3 (SP7, 1:200, Thermo Fisher Scientific), and CD8 (CD8/144B, 1:100, Agilent Dako) were carried out in selected cases. Finally, Thioflavin S staining was performed to assess neuritic plaques in all cases showing AT8 positive immunoreactivity (even minimal) in the cerebral neocortex.

An experienced neuropathologist (P.P.) formulated the final diagnosis, assigned the amyloid phase according to Thal,[30](#acn3697-bib-0030){ref-type="ref"}, [31](#acn3697-bib-0031){ref-type="ref"} the Braak\'s stage of neurofibrillary pathology,[32](#acn3697-bib-0032){ref-type="ref"} the CERAD neuritic plaques score,[33](#acn3697-bib-0033){ref-type="ref"} and classified each case according to the level of AD neuropathologic change (ABC score).[1](#acn3697-bib-0001){ref-type="ref"} To obtain a more continuous measure of A*β* brain load, we also calculated a score after evaluating semiquantitatively immunostained sections from the cerebral cortex (one from each lobe: frontal, temporal, parietal, and occipital), amygdala, hippocampus (CA1 region), striatum, midbrain, and cerebellum. Parenchymal A*β* pathology (Fig. [S2](#acn3697-sup-0001){ref-type="supplementary-material"}) was graded (0--6) as follows: 0‐entirely negative; 2‐rare or sparse deposits (2--4 plaques in at least one 100× microscopic field); 4‐moderate number of deposits (5--10 plaques); 6‐multiple deposits, disseminate (\>10 plaques). An additional point was added when core plaques were also noted. Cerebral amyloid angiopathy (CAA) (Fig. [S2](#acn3697-sup-0001){ref-type="supplementary-material"}) was evaluated in leptomeninges and parenchyma as follows: 0‐entirely negative; 1‐up to two vessels focally involved; 3‐more than half of the vessels involved; and 2‐intermediate between 1 and 3. For each case, a cumulative A*β* score (0--90) was calculated. Similarly, we formulated a score for AD‐related tau neuropathological change by semiquantitative evaluation of p‐tau immunoreactivity (0‐no immunoreactivity; 1‐mild; 2‐moderate; 3‐prominent) in six brain regions, namely transentorhinal cortex, entorhinal cortex, parahippocampal gyrus, middle temporal gyrus, middle frontal gyrus, and occipital cortex. Fine neuritic (threads) tau deposits, neurofibrillary tangles, and thick neuritis, which are part of neuritic plaques, were analyzed separately. Finally, a cumulative score (0--54) (AD tau score) was given.

CSF analysis {#acn3697-sec-0009}
------------

Antemortem CSF was obtained by lumbar puncture at the L3‐L4 or L4‐L5 interspinal space following a standard procedure, centrifuged at 1000*g* for 10 min when showing even mild signs of blood contamination, divided into aliquotes, and stored in polypropylene tubes at −80°C until analysis.

CSF A*β*42, and A*β*40 levels were analyzed using commercially available ELISA kits (INNOTEST A*β*1--42, and INNOTEST A*β*1--40; Innogenetics/Fujirebio) according to the manufacturer\'s instructions.

For the interpretation of A*β*42 results, we used an in‐house cut‐off value of A*β*42 ≤ 495 pg/mL. The calculation of this cut‐off and further details about the pre‐ and analytical variables are reported in supplementary methods in Appendix [S1](#acn3697-sup-0001){ref-type="supplementary-material"}. The ratio of A*β*42 to A*β*40 was calculated according to a previously published formula \[(A*β*42)/(A*β*40)×10\].[15](#acn3697-bib-0015){ref-type="ref"}

Statistical analysis {#acn3697-sec-0010}
--------------------

Statistical analysis was performed using SPSS Statistics version 21 (IBM, Armonk, NY, USA) and Stata SE version 14.2 (StataCorp LLC, Texas, USA). Depending on the data distribution, results were expressed as mean and standard deviation or median and interquartile range (IQR). Due to the non‐normal distribution of biomarker values, Mann‐Whitney *U* test and Kruskal‐Wallis test were applied to test the differences between two or more groups. A Bonferroni correction was applied to multiple comparisons. For both univariate and multivariate linear regression models, A*β*42 and A*β*42/A*β*40 values were transformed into a natural logarithmic scale (ln) to obtain a normal data distribution.

Using univariate linear regression models, we tested the effect of preanalytical variables on CSF biomarker results.

For multivariate linear regression models, we used the A*β* score as a dependent variable and the ln(A*β*42) or the ln(A*β*42/A*β*40) as an independent variable. We tested by univariate models the possible contribution of each demographic variable in predicting the A*β* score and then added to the multivariate model only those with significant associations, using a stepwise approach with the application of the Likelihood ratio test at each step. We considered as possible covariates the age, sex, disease duration, interval between CSF collection and death, ApoE *ε*4 allele (presence or absence), prion disease (presence or absence), and AD tau score. Finally, we applied Bayesian information criteria (BIC)[34](#acn3697-bib-0034){ref-type="ref"} to select the best performing model in the comparison between the one with ln(A*β*42) and the one with ln(A*β*42/A*β*40).

ROC analyses were obtained to compare the diagnostic value of A*β*42 and A*β*42/A*β*40 ratio. The optimal cut‐off value for biomarkers was chosen using the maximized Youden index. The Delong test[35](#acn3697-bib-0035){ref-type="ref"} was used to compare the areas under the curve (AUC) of A*β*42 and A*β*42/A*β*40 ratio. Differences were considered statistically significant at *P*  \<  0.05.

Results {#acn3697-sec-0011}
=======

Demographics, CSF biomarker values, and AD‐related neuropathology scores (Table [1](#acn3697-tbl-0001){ref-type="table"}) {#acn3697-sec-0012}
-------------------------------------------------------------------------------------------------------------------------

###### 

Demographics, CSF biomarker data, and AD‐related neuropathology scores

  -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Demographics                                                                                       
  Mean age at onset -- years ± SD                                                                    68.5 ± 9.3
  Female -- *n* (%)                                                                                  106 (50.2%)
  Median disease duration ‐ months (IQR)                                                             4 (2.5--9)
  Median interval between LP and death ‐ months (IQR)                                                1.5 (1--4)
  ApoE genotype -- *n* (%)                                                                           *ε*4/*ε*4: 5 (2.4); *ε*3/*ε*4: 30 (14.2); *ε*2/*ε*4: 1 (0.4); *ε*3/*ε*3: 158 (74.9); *ε*2/*ε*3: 17 (8.1)
  CSF biomarker values                                                                               
  A*β*42 pg/mL ‐ median (IQR)                                                                        522 (373--763)
  A*β*40 pg/mL ‐ median (IQR)                                                                        5030 (3406--6951)
  A*β*42/A*β*40 ‐ median (IQR)                                                                       1.098 (0.806--1.435)
  AD‐related neuropathology scores                                                                   
  Thal\'s A*β* phase[30](#acn3697-bib-0030){ref-type="ref"} ‐ *n* (%)                                0: 80 (37.9); 1--2: 56 (26.6); 3: 33 (15.6); 4--5: 42 (19.9)
  Braak\'s NF stage[31](#acn3697-bib-0031){ref-type="ref"} ‐ *n* (%)                                 0: 114 (54.0); I‐II: 58 (27.5); III‐IV: 34 (16.1); V‐VI: 5 (2.4)
  Level of AD neuropathological change (ABC score)[1](#acn3697-bib-0001){ref-type="ref"} ‐ *n* (%)   Not: 82 (38.9); Low: 95 (45.0); Intermediate: 29 (13.7); High: 5 (2.4)
  CAA -- *n* (%)                                                                                     Negative: 148 (70.1); Type 1: 4 (1.9); Type 2: 59 (28.0)
  A*β* score -- median (IQR)                                                                         7.0 (0--30)
  AD tau score ‐ median (IQR)                                                                        3 (0.5--8)
  -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------

A*β*, amyloid beta; AD, Alzheimer\'s disease; CAA; cerebral amyloid angiopathy; IQR, interquartile range; LP; lumbar puncture; n, number of cases; NF, neurofibrillary pathology; SD, standard deviation.

John Wiley & Sons, Ltd

Patients with AD or AD/DLB mixed pathology showed significantly lower A*β*42 levels than those with prion disease (*P* \< 0.001), inflammatory diseases (*P* = 0.013), and other RPDs (*P* = 0.001) (Table [2](#acn3697-tbl-0002){ref-type="table"}). Conversely, the levels of A*β*42 did not vary significantly among non‐AD diagnostic groups (e.g., prion disease, inflammatory diseases and other RPDs). There were also no significant differences in the CSF levels of A*β*40 between AD or AD/DLB, prion disease, inflammatory diseases, and the other RPD groups. The results of CSF A*β*42 and A*β*40 analysis in patients with and without CAA and the effects of preanalytical variables are shown in Appendix [S1](#acn3697-sup-0001){ref-type="supplementary-material"}.

###### 

Distribution of A*β*42 an A*β*40 levels across different diagnostic groups

           AD+AD/DLB           Prion disease       Other RPDs          Inflammatory Diseases
  -------- ------------------- ------------------- ------------------- -----------------------
  N        17                  160                 26                  8
  A*β*42   270 (202--370)      568 (404--772)      506 (312--778)      402 (370--901)
  A*β*40   4254 (3057--7009)   5054 (3392--6855)   5094 (3663--7939)   4737 (3095--8861)

Data are expressed as median and interquartile range.

A*β*, amyloid beta; AD, Alzheimer\'s disease; DLB, dementia with Lewy bodies; RPD, rapidly progressive dementia.

John Wiley & Sons, Ltd

Relationship between CSF A*β*42 levels and A*β*42/A*β*40 values with AD neuropathology {#acn3697-sec-0013}
--------------------------------------------------------------------------------------

Patients with no A*β* deposits had higher levels of A*β*42 (666 pg/mL, IQR 405--835) than those with A*β* deposits (465 pg/mL, IQR 355--655) with 33.8% of subjects of the first group and 53.7% of the latter having A*β*42 levels below the threshold of 495 pg/mL. A comparison between subjects with high, intermediate, and low degree of AD pathology showed A*β*42 levels below threshold in, respectively, 80% (*n* = 4), 86.2% (*n* = 25) and 44.2% (*n* = 42) of cases. Similarly, 88.1% of subjects in Thal\'s phase 4 or 5 (*n* = 37), 48.3% of those in phase 3 (*n* = 16) and 33.6% of those in phase 1--2 (*n* = 19) had A*β*42 levels ≤495 pg/mL. As for A*β*42, the A*β*42/A*β*40 ratio showed higher values in subjects without A*β* deposits (1.383, IQR 1.111--1.855) than in those with A*β* deposits (0.893, IQR 0.682--1.179). Values of A*β*42/A*β*40 ratio and A*β*42 levels according to each Thal\'s phase of A*β* deposition are shown in Figure [1](#acn3697-fig-0001){ref-type="fig"}.

![Comparison of A*β* neuropathological score, CSF A*β*42 levels (pg/mL), and CSF A*β*42/A*β*40 ratio across the Thal\'s phases of A*β* pathology.[31](#acn3697-bib-0031){ref-type="ref"} Data are expressed as median and interquartile range (IQR).](ACN3-6-263-g001){#acn3697-fig-0001}

Correlations between CSF biomarkers and amyloid‐beta pathology {#acn3697-sec-0014}
--------------------------------------------------------------

In the total cohort, the A*β* score showed a better correlation with ln(A*β*42/A*β*40) (*R* ^2^ = 0.506, *β *= −0.713, *P* \< 0.001) than with ln(A*β*42) (*R* ^2^ = 0.206, *β *= −0.458, *P* \< 0.001) (Table [3](#acn3697-tbl-0003){ref-type="table"} and Figure [2](#acn3697-fig-0002){ref-type="fig"}). Accordingly, the model including ln(A*β*42/A*β*40) yielded a lower BIC value (1096.1) than that including ln(A*β*42) (1196.3), suggesting that ln(A*β*42/A*β*40) is a better explanatory variable. We found similar associations \[ln(A*β*42): *R* ^2^ = 0.547, *β *= −0.239, *P* \< 0.001; ln(A*β*42/A*β*40): *R* ^2^ = 0.634, *β *= −0.460, *P* \< 0.001\] and a lower BIC value for the model with ln(A*β*42/A*β*40) (1031.2) than that with ln(A*β*42) (1075.4), after accounting for covariates by multivariate regression analysis (Table [3](#acn3697-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate regression models to predict postmortem cerebral amyloid‐beta pathology

  Variable                             Model *R* ^2^   Model *P* value   B (95% CI)                     *SE*     Beta[a](#acn3697-note-0008){ref-type="fn"}   *P* value
  ------------------------------------ --------------- ----------------- ------------------------------ -------- -------------------------------------------- -----------
  A\) Total cohort                                                                                                                                            
  Univariate models                                                                                                                                           
  Ln (A*β*42)                          0.206           \<0.001           −17.368 (−21.970 to −12.766)   2.335    −0.458                                       
  Ln (A*β*42/A*β*40)                   0.506           \<0.001           −30.538 (−34.633 to −26.442)   2.077    −0.713                                       
  Multivariate models                                                                                                                                         
  Ln (A*β*42)                          0.547           \<0.001           −9.000 (−12.822 to −5.177)     1.939    −0.239                                       \<0.001
  Age at LP (y)                                                          0.529 (0.327 to 0.732)         0.103    0.265                                        \<0.001
  AD tau score                                                           0.925 (0.700 to 1.149)         0.114    0.468                                        \<0.001
  ApoEε4                                                                 6.667 (1.968 to 11.365)        2.383    0.135                                        0.006
  Prion disease                                                          4.435 (0.100 to 8.771)         2.199    0.102                                        0.045
  Intercept                                                              24.813 (−2.223 to 51.850)      13.712   --                                           0.072
  Ln (A*β*42/A*β*40)                   0.634           \<0.001           −19.618 (−24.098 to −15.138)   2.272    −0.460                                       \<0.001
  Age at LP (y)                                                          0.215 (0.023 to 0.408)         0.098    0.108                                        0.029
  AD tau score                                                           0.759 (0.553 to 0.966)         0.105    0.385                                        \<0.001
  ApoEε4                                                                 6.182 (1.971 to 10.394)        2.136    0.125                                        0.004
  Prion disease                                                          5.142 (1.247 to 9.038)         1.976    0.118                                        0.010
  Intercept                                                              −7.764 (−21.334 to 5.806)      6.882    --                                           0.261
  B\) Cohort with A*β*42 ≤ 495 pg/mL                                                                                                                          
  Univariate models                                                                                                                                           
  Ln (A*β*42)                          0.040           0.026             −14.875 (−27.961 to −1.790)    6.592    −0.224                                       
  Ln (A*β*42/A*β*40)                   0.591           \<0.001           −31.042 (−36.227 to −25.857)   2.612    −0.772                                       
  Multivariate models                                                                                                                                         
  Ln (A*β*42)                          0.536           \<0.001           −2.376 (−12.252 to 7.501)      4.971    −0.036                                       0.634
  Age at LP (y)                                                          0.676 (0.343 to 1.010)         0.168    0.331                                        \<0.001
  AD tau score                                                           0.922 (0.597 to 1.248)         0.164    0.501                                        \<0.001
  ApoEε4                                                                 5.452 (−1.335 to 12.240)       3.416    0.114                                        0.114
  Prion disease                                                          1.813 (−4.936 to 8.562)        3.397    0.041                                        0.595
  Intercept                                                              −21.190 (−81.537 to 39.156)    30.371   --                                           0.487
  Ln (A*β*42/A*β*40)                   0.686           \<0.001           −20.293 (−26.440 to −14.146)   3.094    −0.507                                       \<0.001
  Age at LP (y)                                                          0.335 (0.042 to 0.627)         0.147    0.164                                        0.025
  AD tau score                                                           0.588 (0.306 to 0.871)         0.142    0.320                                        \<0.001
  ApoEε4                                                                 4.264 (−1.321 to 9.850)        2.811    0.089                                        0.133
  Prion disease                                                          3.981 (−1.518 to 9.480)        2.767    0.090                                        0.154
  Intercept                                                              −9.834 (−29.956 to 10.289)     10.127   --                                           0.334

Optimal multivariate linear regression models using the A*β* postmortem pathology score as the dependent variable and either CSF ln(A*β*42) levels or ln(A*β*42/A*β*40) as independent variable after adjusting for covariates (age at LP, AD tau score, presence of prion disease, presence of ApoE *ε*4).

A*β*, amyloid beta; AD, Alzheimer\'s disease; CI, interval of confidence; ln, natural logarithm; LP, lumbar puncture; SE, standard error; y, years.

standardized Beta.

John Wiley & Sons, Ltd

![Correlations between CSF ln(A*β*42) levels, ln(A*β*42/A*β*40) values, and A*β*‐related pathology. (A) A significant negative correlation is seen between CSF ln(A*β*42) levels and A*β* pathology score (*R* ^2^ = 0.206, *β* = −0.458, *P* \< 0.001). (B) In comparison to (A) the negative correlation between CSF ln(A*β*42/A*β*40) and A*β* pathology score is significantly higher (*R* ^2^ = 0.506, *β* = −0.713, *P* \< 0.001).](ACN3-6-263-g002){#acn3697-fig-0002}

When we considered only the cases with A*β*42 levels lower than ≤495 pg/mL (*n* = 98), the difference of the correlation coefficients between A*β* score and ln(A*β*42/A*β*40) (*R* ^2^ = 0.591, *β *= −0.772, *P* \< 0.001) and A*β* score and ln(A*β*42) (*R* ^2^ = 0.040, *β* = −0.224, *P* = 0.026) increased further. The latter result was confirmed after adjusting for covariates \[ln(A*β*42): *R* ^2^ = 0.536, *β* = −0.036, *P* \< 0.001; ln(A*β*42/A*β*40): *R* ^2^ = 0.686, *β* = −0.507, *P* \< 0.001\]. In both analyses, either not‐adjusted or adjusted for covariates, the BIC values of the models with ln(A*β*42/A*β*40) were lower (513.6 and 486.3, respectively) than those of the models with ln(A*β*42) (597.2 and 523.6).

Diagnostic accuracy of CSF amyloid‐beta‐related biomarkers {#acn3697-sec-0015}
----------------------------------------------------------

Based on our intralaboratory A*β*42 cut‐off value, we extended the assessment of the relative diagnostic accuracy of each amyloid‐related biomarker to the group of patients with A*β*42 levels lower than 495 pg/mL. In this group and in the total cohort, we performed ROC analyses according to: (1) the presence of Thal\'s phase 3--5 versus 0--2, (2) the presence or absence of AD pathology as assessed by the ABC score (AD+ vs. AD‐), and (3) the presence of a intermediate‐high versus low‐not AD pathology.

In the total cohort (*N* = 211), the A*β*42/A*β*40 ratio was superior to A*β*42 in the distinction between cases with or without AD pathology (AUC 0.818 ± 0.028 vs. 0.643 ± 0.039). As expected, the analyses (1) and (3) yielded similar results (Table [4](#acn3697-tbl-0004){ref-type="table"}). Most significantly, using cut‐off values of 405 pg/mL for A*β*42 and 0.810 for A*β*42/A*β*40, ratio the analyses yielded 75.7% or 87.0% sensitivity and 76.5% or 88.2% specificity, respectively, in the distinction between cases with an intermediate‐high level of AD pathology and those with low level and no AD pathology. AUC, sensitivity, and specificity values for all analyses are reported in Table [4](#acn3697-tbl-0004){ref-type="table"}. For every ROC analysis, the AUC of A*β*42/A*β*40 ratio was significantly higher than that of A*β*42 at Delong test.

###### 

ROC analyses in the total cohort

                                                   Analysis                                
  ------------------------------------------------ --------------- --------- ------ ------ --------
  \(1\) Thal\'s phase: 3--5 vs. 0--2                                                       
  A*β*42                                           0.755 ± 0.034   \<466     72.5   69.3   0.0001
  A*β*42/A*β*40                                    0.905 ± 0.021   \<0.955   84.6   80.0   
  \(2\) ABC score: AD+ vs. AD‐                                                             
  A*β*42                                           0.643 ± 0.039   \<622     56.1   71.3   0.0004
  A*β*42/A*β*40                                    0.818 ± 0.028   \<1.131   72.0   69.8   
  \(3\) ABC score: Intermediate‐high vs. not‐low                                           
  A*β*42                                           0.808 ± 0.035   \<405     75.7   76.5   0.0174
  A*β*42/A*β*40                                    0.900 ± 0.027   \<0.810   87.0   88.2   

A*β*, amyloid beta; AD, Alzheimer\'s disease; AUC, area under the curve; Sens, sensitivity; Spec, specificity.
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When we restricted the analysis to patients with A*β*42 levels lower than 495 pg/mL, we observed a significant increase in the accuracy of A*β*42/A*β*40 ratio (AUC 0.939 ± 0.022) in the prediction of Thal\'s phases (3--5 vs. 0--2), whereas the accuracy of A*β*42 decreased (AUC 0.613 ± 0.057) (*P* \< 0.001). The same trend, with the ratio showing significantly higher values (AUC 0.888 ± 0.032; 0.869 ± 0.036) in comparison to A*β*42 (AUC 0.518 ± 0.064; 0.650 ± 0.058) (*P* \< 0.001 and *P* = 0.002), was observed by considering the AD pathology score (analyses 2 and 3, respectively).

Details about the distribution of AD pathological changes in the patient cohort according to given ranges of values of CSF A*β*42/A*β*40 ratio are provided in Figure [3](#acn3697-fig-0003){ref-type="fig"}.

![Distribution of AD pathological changes at each given range of CSF A*β*42/A*β*40 ratio values. A*β*, amyloid beta; NF, neurofibrillary pathology; n, number of cases.](ACN3-6-263-g003){#acn3697-fig-0003}

Discussion {#acn3697-sec-0016}
==========

The results of the present study demonstrate that, in patients with RPD of various etiology, the measurement of A*β*42/A*β*40 ratio in CSF samples taken shortly before death predicts better than CSF A*β*42 levels the burden of A*β* brain deposits. The assessment of diagnostic accuracy in pathologically verified case series represents the gold standard for biomarker validation. Nevertheless, only a few studies have consistently correlated A*β*42 values in vivo with postmortem A*β* pathology,[7](#acn3697-bib-0007){ref-type="ref"}, [8](#acn3697-bib-0008){ref-type="ref"} while none has, to date, specifically considered the predictive value of the A*β*42/A*β*40 ratio on A*β* pathology. Moreover, such studies are hampered by the long latency between the in vivo and postmortem assessments, which are especially relevant considering the current need to validate the diagnostic biomarkers for AD and other neurodegenerative diseases in the prodromal or even preclinical stage.[10](#acn3697-bib-0010){ref-type="ref"}, [36](#acn3697-bib-0036){ref-type="ref"}, [37](#acn3697-bib-0037){ref-type="ref"} Brains affected by CJD and other RPDs provide the unique opportunity to correlate the CSF findings with the postmortem neuropathology within a short time interval.[13](#acn3697-bib-0013){ref-type="ref"} Moreover, by including patients who were virtually asymptomatic before the onset of the RPD, such a series represents well the population in which the accuracy of in vivo markers for AD needs to be validated the most (i.e., elderly asymptomatic patients with various degree of AD pathology).[10](#acn3697-bib-0010){ref-type="ref"}, [36](#acn3697-bib-0036){ref-type="ref"}, [37](#acn3697-bib-0037){ref-type="ref"}

According to our data, the A*β*42/A*β*40 ratio performs significantly better than A*β*42 alone in predicting the whole spectrum of AD pathological changes, not only the burden of A*β* deposits. However, the added value of the ratio appears to decrease with increasing severity of AD pathology, being highest in cases with low or even absent A*β* deposition, which especially underlines the importance of the A*β*42/A*β*40 ratio in the identification of the "false positive" samples with low Aβ42 reflecting causes other than the A*β*‐related pathology. These confounders are well known and include not only preanalytical factors, such as the interval between collection and freezing, sample exposure to storage surfaces, and assay measurement variation,[10](#acn3697-bib-0010){ref-type="ref"}, [11](#acn3697-bib-0011){ref-type="ref"}, [38](#acn3697-bib-0038){ref-type="ref"} and comorbidities affecting A*β* metabolism, but also the individual variability in CSF A*β*42 production. Indeed, evidence indicates that CSF A*β* peptide concentration varies between individuals and some subjects may be constitutively low A*β*42 producers.[16](#acn3697-bib-0016){ref-type="ref"} Moreover, pathological changes other than A*β* deposition such as synaptic loss might contribute to the reduction of A*β* levels, including A*β*42.[39](#acn3697-bib-0039){ref-type="ref"} Accordingly, in the clinical setting, the occurrence of indeterminate results, revealing abnormal A*β*42 levels and normal t‐tau and p‐tau, is a significant problem limiting the diagnostic accuracy of CSF biomarkers in suspected AD cases.[6](#acn3697-bib-0006){ref-type="ref"}, [23](#acn3697-bib-0023){ref-type="ref"}, [24](#acn3697-bib-0024){ref-type="ref"} In this respect, the use of t‐tau/A*β*42 or p‐tau/A*β*42 ratios has shown a better diagnostic performance in comparison to the single biomarker determination,[10](#acn3697-bib-0010){ref-type="ref"}, [40](#acn3697-bib-0040){ref-type="ref"} and with an overall accuracy comparable to that of A*β*42/A*β*40 ratio.[41](#acn3697-bib-0041){ref-type="ref"}, [42](#acn3697-bib-0042){ref-type="ref"} However, given that CSF tau and A*β* reflect distinct pathological processes which have different importance regarding both specificity and time of appearance, the use of a ratio targeted to a single proteinopathy appears more rationale and might even be more accurate in preclinical AD. Indeed, according to the prevailing amyloid hypothesis, A*β* aggregation represents the primary and most specific pathological event in AD since tau deposition may occur secondarily to many other pathologies. Accordingly, AD biomarkers are increasingly being distinct in A*β* deposition, tau pathology, and neurodegeneration, following the A/T/N classification.[36](#acn3697-bib-0036){ref-type="ref"}, [43](#acn3697-bib-0043){ref-type="ref"} Consequently, the identification and implementation of the biomarkers with the highest specificity and accuracy in measuring the degree of A*β* pathology should be the primary goal,[36](#acn3697-bib-0036){ref-type="ref"} especially in the earlier disease stages when tau pathology is not widespread yet. The results of a recent study showing that the accuracy of \[18F\]flortaucipir PET in the discrimination between AD and other neurodegenerative disorders is lower at the prodromal stage of AD support this conclusion.[44](#acn3697-bib-0044){ref-type="ref"} In this regard, the A*β*42/A*β*40 ratio is emerging as the best current candidate CSF biomarker for A*β* pathology since it minimizes biases linked to preanalytical and analytical factors, and the inter‐individual variability of A*β* production.[18](#acn3697-bib-0018){ref-type="ref"}, [25](#acn3697-bib-0025){ref-type="ref"}, [26](#acn3697-bib-0026){ref-type="ref"} In this context, our results do not propose a novel marker, but rather provide extensive neuropathological data, from a large patient cohort, in support of the added value of the A*β*42/A*β*40 ratio in the diagnostic AD assessment. The results obtained recommend the use of the A*β*42/A*β*40 ratio in the clinical evaluation of AD pathology using CSF biomarkers, especially in cases with an "indeterminate" CSF profile, characterized by normal t‐tau and p‐tau and low A*β*42 levels.

Limitations of the present study mainly concern the inclusion of cases with CJD and other causes of RPD such as encephalitis, in which previous studies documented a reduction of mean CSF A*β*42 levels in comparison to normal subjects.[45](#acn3697-bib-0045){ref-type="ref"}, [46](#acn3697-bib-0046){ref-type="ref"} However, in our cohort, we found comparable levels of CSF A*β*42 among the non‐AD diagnostic groups. Additionally, we obtained the same correlation between amyloid CSF biomarkers and A*β* score after accounting for the presence of prion disease, which indicates that the findings are not only related to a CJD‐specific effect. Finally, the influence of copathologies on A*β* levels in the CSF has also a significant impact in clinical practice given that mixed brain pathologies frequently affect the elderly population.[47](#acn3697-bib-0047){ref-type="ref"} While the unbalanced cohort, mainly represented by CJD cases, is a recognized limit of our study, the focus on CJD and other RPDs provided the unique opportunity to analyze CSF data on samples collected, on average, only a few months before death and in several brains with a degree of A*β* pathology corresponding to presymptomatic AD.

We choose not to include CSF t‐tau and p‐tau data in our analyses because of the high proportion of CJD cases in the cohort. Indeed, CSF t‐tau and, at least in some subtypes, p‐tau levels may increase in CJD independently from the coexisting AD pathology. Moreover, previous data from our group demonstrated that in typical sCJD (e.g., MM1 subtype), in which p‐tau CSF levels are not significantly elevated, p‐tau fails to consistently discriminate between patients with or without age‐ or AD‐related neurofibrillary pathology when tau deposition is limited to the medial temporal lobe (Braak stages I--III), the stages most commonly associated with early asymptomatic AD.[13](#acn3697-bib-0013){ref-type="ref"}

In conclusion, the present data provide strong support for the use of CSF A*β*42/A*β*40 ratio as a biomarker for A*β*‐related pathology (A category in the A/T/N scheme) in clinical practice and its introduction in the research diagnostic criteria for AD.
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